Minister of Health Promotes Local Medicine Production for the Romanian Healthcare System

The development of Romania's pharmaceutical industry is becoming a strategic priority for improving access to medicines, particularly for the elderly population, which relies heavily on chronic treatments and affordable generic drugs.

A recent official visit to one of the country's leading pharmaceutical manufacturing plants highlights the importance of domestic production for the sustainability of the healthcare system. With nearly 1,000 employees and more than 100 million packs produced annually, the local pharmaceutical industry demonstrates considerable potential that could directly benefit elderly patients.

For Romanian seniors, dependence on imported medicines can create vulnerabilities in access to essential treatments. Strengthening domestic production could provide greater stability in the supply of medicines for chronic conditions common in old age, such as diabetes, hypertension, and cardiovascular problems.

Generic medicines represent a crucial component for older people, often being the only financially accessible option for long-term treatments. Developing local production capacity in this segment could reduce costs and improve the availability of treatments for pensioners on limited incomes.

Exports to 25 countries across the European Union and the CIS (Commonwealth of Independent States) region demonstrate that Romanian manufacturing standards are internationally recognised. This gives families confidence that locally produced medicines meet the stringent safety and efficacy criteria required for elderly care.

Initiatives to strengthen the local pharmaceutical industry come at a time when Romania is facing major demographic challenges, with an ageing population that requires continuous access to medicines. A resilient healthcare system, underpinned by domestic production, could guarantee that seniors have uninterrupted access to the treatments they depend on.

Ongoing dialogue with the local pharmaceutical industry aims at implementing policies that protect and develop these strategic capabilities. For older people and their families, this means better prospects for access to essential medicines, independent of fluctuations in the international market.